Ocrelizumab

From Self-sufficiency
Jump to: navigation, search
Ocrelizumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CD20
Identifiers
CAS Number 637334-45-3
ATC code none
Chemical data
Formula C6494H9978N1718O2014S46
Molar mass 148 kDa[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets mature B lymphocytes[1] and hence is an immunosuppressive drug candidate. It is under development by Hoffmann–La Roche's subsidiary Genentech, and Biogen Idec.

It had reached Phase III clinical trials for rheumatoid arthritis[2] and lupus erythematosus[3] , and Phase II for multiple sclerosis[4] and hematological cancer.[5]

In March 2010, Roche announced the suspension of clinical trials in rheumatoid arthritis and lupus erythematosus. This step followed excess deaths due to opportunistic infections. Development for multiple sclerosis continues.[6]

See also

Other CD20 antagonists :

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. K. John Morrow Jr (2008-06-15). "Methods for Maximizing Antibody Yields". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. p. 36. Retrieved 2008-07-06.  (Note: information included in this article only found in table present in print version of article.)
  2. Kausar, F; Mustafa, K; Sweis, G; Sawaqed, R; Alawneh, K; Salloum, R; Badaracco, M; Niewold, TB; Sweiss, NJ (2009). "Ocrelizumab: a step forward in the evolution of B-cell therapy". Expert opinion on biological therapy. 9 (7): 889–95. doi:10.1517/14712590903018837. PMID 19463076. 
  3. http://www.clinicaltrials.gov/ct2/show/NCT00539838 A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
  4. http://www.clinicaltrials.gov/ct2/show/NCT00676715 A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.
  5. Hutas, G (2008). "Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies". Current opinion in investigational drugs (London, England : 2000). 9 (11): 1206–15. PMID 18951300. 
  6. Katie Reid (2010-03-08). Update 2. Roche suspends arthritis treatment after deaths. Reuters. Retrieved 2010-03-08.